CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest

BACKGROUND: Cell cycle dysregulation is common in human malignancies, and CDK4/6 inhibitors targeting cell cycle have potential antitumor activity. SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. However, the role of SHR6390 in esophageal squamous cell carcinom...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Transl Med
Main Authors: Wang, Jiayuan, Li, Qingqing, Yuan, Jiajia, Wang, Jingyuan, Chen, Zuhua, Liu, Zhentao, Li, Zhongwu, Lai, Yumei, Gao, Jing, Shen, Lin
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5457542/
https://ncbi.nlm.nih.gov/pubmed/28578693
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-017-1231-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados